Pacific Biosciences of Californ vs Pfizer, Inc. — Stock Comparison
Q·Score Breakdown
5.5
Neutral
Overall
6.5
Neutral
Quality
Health
Growth
Valuation
Sentiment
PACB
Revenue expanding at 14% year-over-year.
⚠ low return on equity (-213%).
PFE
Strong profitability with 12% net profit margins.
⚠ analyst sentiment is cautious.
Analyst Consensus
HOLD
Target $2.38 (+48.4%)
6 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts
Fundamentals
PACB
PFE
—
Trailing P/E
19.4×
-3.8×
Forward P/E
9.4×
0.0%
Profit Margin
12.4%
34.3%
Gross Margin
75.8%
-213.5%
ROE
8.9%
13.8%
Revenue Growth
-1.2%
—
Earnings Growth
—
2.33
Beta
0.39
—
Price / Book
—
$497M
Market Cap
$149.8B
$1 – $3
52-Week Range
$22 – $29
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →